Post-fracture Medication and Mortality

National Cheng-Kung University

Status: Completed

Conditions: Mortality; Drug Therapy; Osteoporosis; Adherence, Medication; Osteoporosis Fracture

Treatments: Drug: Anti-osteoporosis medications

Study type: Observational

Funder types: Other

Identifiers

NCT05366621

Osteoporosis and Mortality

Details and patient eligibility

About

Osteoporotic fracture is a common public-health problem in the whole world. Although postfracture usage of anti-osteoporosis medications, may reduce mortality, recent results have been inconsistent. The investigators aim to examine associations between osteoporosis medication and mortality in older adults and any type of fracture patients. The investigators also aim to discuss the pleiotropic effects of different types of anti-osteoporosis medications.

Full description

Osteoporotic fracture has become a serious health and economic burden as life expectancy increases. In a WHO report, the burden of osteoporotic fractures in 2002 was 2.8 million disability-adjusted life years, which is more than that for hypertension and slightly less than that for diabetes mellitus or chronic obstructive pulmonary diseases. Many patients who have had a diagnosed fracture have never been diagnosed with osteoporosis, therefore, closing the gap in osteoporosis treatment is important. This situation is primarily due to the fact that osteoporosis symptoms are often not recognized until a fracture occurs. Osteoporotic fractures, especially those of the hip and vertebral, are associated with an increased risk of death. Early detection of high risk for osteoporotic fractures is important; however, post-fracture management, especially interventions intended to lower mortality, is an emerging public health issue in rapidly aging societies. The burden of osteoporotic fracture is higher than that of hypertension, however, osteoporosis is always given less attention than other chronic diseases by health professionals and the general population.

Enrollment: 216,155 patients

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Newly diagnosed osteoporosis and hip fracture are defined as a claim record from the NHIRD between 2009 and 2017.

Exclusion criteria

• Patients with a diagnosis of osteoporosis or osteoporotic fractures in 2008 or before were excluded.

Trial design

216,155 participants in 2 patient groups

Used osteoporosis medication

Description:

Patients who had used osteoporosis medication after osteoporotic fractures.

Treatment:

Drug: Anti-osteoporosis medications

Did not use osteoporosis medication

Description:

Patients who didn't use osteoporosis medication after osteoporotic fractures.

Treatment:

Drug: Anti-osteoporosis medications